Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Genética | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
ClinicalTrials.gov
Institutional Registries of Rare Diseases at Hospital Italiano de Buenos Aires (HIBA)
OBSERVATIONAL
Inicio: 1 de jul de 2024
ID: NCT06573723
Completado
ClinicalTrials.gov
A Prospective, Observational, Multi-center, International Study to Validate a Non-invasive Preimplantation Genetic Test for Embryo Aneuploidy in the Spent Culture Media (niPGT-A).
OBSERVATIONAL
Inicio: 27 de abr de 2018
ID: NCT03520933
Completado
Fase 3
ClinicalTrials.gov
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
INTERVENTIONAL
Inicio: 14 de feb de 2019
ID: NCT03759379
Completado
Fase 4
ClinicalTrials.gov
A Phase IV Open-label, Single-arm, Single-dose, Multicenter Study to Evaluate the saFEty, toLerability and effIcacy of Gene Replacement Therapy With intravenousOAV101(AVXS101) in Pediatric Patients From Latin America With Spinal Muscular Atrophy (SMA) - OFELIA
INTERVENTIONAL
Inicio: 4 de nov de 2021
ID: NCT05073133
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
INTERVENTIONAL
Inicio: 8 de abr de 2014
ID: NCT02163694
Completado
ClinicalTrials.gov
Post Authorization Study to Monitor Efficacy, Effectiveness and Safety of Lanadelumab (Takhzyro®) in Patients Aged 12 Years and Older With Hereditary Angioedema (HAE) in Argentina
OBSERVATIONAL
Inicio: 28 de jul de 2021
ID: NCT04955964
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
INTERVENTIONAL
Inicio: 11 de dic de 2023
ID: NCT06065748
Reclutando
Fase 3
ClinicalTrials.gov
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease
INTERVENTIONAL
Inicio: 22 de nov de 2024
ID: NCT06647498
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)
INTERVENTIONAL
Inicio: 4 de mar de 2022
ID: NCT05215340
Activo, no recluta
Fase 3
ClinicalTrials.gov
An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
INTERVENTIONAL
Inicio: 4 de ene de 2022
ID: NCT05071300
Completado
Fase 3
ClinicalTrials.gov
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
INTERVENTIONAL
Inicio: 1 de nov de 2013
ID: NCT01960348
Completado
Fase 4
ClinicalTrials.gov
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
INTERVENTIONAL
Inicio: 1 de sept de 2011
ID: NCT01419249
Completado
ClinicalTrials.gov
Biological Effects in Consumers of Resveratrol-enriched Wine
OBSERVATIONAL
Inicio: 15 de jul de 2022
ID: NCT05981053
Aún no recluta
ClinicalTrials.gov
Comprehensive Program for Hereditary Transthyretin Amyloidosis
OBSERVATIONAL
Inicio: 1 de oct de 2025
ID: NCT07213297
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
INTERVENTIONAL
Inicio: 3 de may de 2022
ID: NCT04879329
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
INTERVENTIONAL
Inicio: 11 de ene de 2023
ID: NCT05555732
Terminado
Fase 2
ClinicalTrials.gov
A Phase 1b/2 Study of Derazantinib as Monotherapy and Combination Therapy With Paclitaxel, Ramucirumab or Atezolizumab in Patients With HER2-negative Gastric Adenocarcinoma Expressing FGFR2 Genetic Aberrations
INTERVENTIONAL
Inicio: 6 de oct de 2020
ID: NCT04604132
Desconocido
Fase 4
ClinicalTrials.gov
Effectiveness of Weekly and Daily Iron Supplementation for the Prevention of Iron-deficiency Anemia in Infants. Impact on Genomic Stability
INTERVENTIONAL
Inicio: 1 de ago de 2017
ID: NCT03359447
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age With Achondroplasia: PROPEL 3
INTERVENTIONAL
Inicio: 10 de nov de 2023
ID: NCT06164951
Completado
Fase 3
ClinicalTrials.gov
A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions
INTERVENTIONAL
Inicio: 1 de nov de 2007
ID: NCT00566657
Anterior
1
2
3
...
434
Siguiente
Filtros